The Alzheimer’s diagnostics company will relocate headquarters and expand CLIA-certified lab operations to the Cortex Innovation District by late 2026.
C2N Diagnostics will triple the size of its St. Louis operations with a move to an 82,451-square-foot facility at Catalyst, Powered by WashU, in the Cortex Innovation District.
The specialty diagnostics company, known for its PrecivityAD2 blood test for Alzheimer’s disease detection, expects to begin relocating its headquarters and expanding its CAP-accredited, CLIA-certified laboratory operations in late 2026. The new facility will occupy the first three floors of the former Goodwill Industries International site, which Washington University is redeveloping.
“This news is a testament to the enthusiastic backing we’ve received in St. Louis, the extremely talented team members we employ, and the health care professionals who’ve embraced our technology and premium quality testing services,” says Dr Joel Braunstein, CEO of C2N, in a release.
The expanded laboratory will leverage bioautomation and high-resolution, high-throughput proteomic testing capabilities. C2N will maintain its existing ISO 13485:2016 compliant facility, converting it into a center for multi-omic solutions and advanced analytical platforms supporting its biopharmaceutical research services and medical technology business units.
Expanding Biomarker Pipeline
C2N reports more than 50,000 Precivity analytes have been documented in peer-reviewed publications, with over 150 academic, clinical, and research collaborations globally using Precivity biomarkers. The company is expanding its biomarker pipeline to include advanced assays targeting tau pathology and Parkinson’s disease research, while developing technologies to decentralize mass spectrometry testing.
The company’s PrecivityAD2 blood test helps healthcare professionals detect amyloid plaques in the brain, a pathological hallmark of Alzheimer’s disease, to inform medical management and treatment decisions.
Recent company developments include investment from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation; a partnership with The Michael J. Fox Foundation; medical device registration in the United Kingdom; and Canadian expansion.
Regional Innovation Hub
“When WashU acquired the former Goodwill building in the Cortex Innovation District, we saw more than a property—we saw potential,” says Doug Frantz, vice chancellor for innovation and commercialization at WashU, in a release. “Catalyst will lower the barrier for late-stage start-ups such as C2N to find the space, resources and community that will accelerate their breakthroughs to market.”
C2N was co-founded by Washington University researchers with underlying technology spun out of the university. The company currently operates from facilities at BioSTL at 4340 Duncan Ave and CIC at 20 S Sarah St within Cortex.
“C2N’s expansion in St. Louis is yet another example of our region’s strength in neuroscience research,” says Dustin Allison, interim CEO of Greater St. Louis Inc, in a release. “C2N’s investment here is not only deeply important to human health, but also to our region’s economic development.”
C2N’s mass spectrometry-based biomarker services support clinical decision-making for patient care, clinical trials for neurodegeneration treatments, and research tools for understanding disease mechanisms. The company maintains collaborations with multinational pharmaceutical and biotech companies, academic institutions, the National Institute on Aging, and research partnerships with laboratories including Grupo Fleury, Healius, Mediford, Mayo Clinic Laboratories and Unilabs.
Photo caption: C2N Diagnostics is tripling the size of its operations in its hometown.
Photo credit: C2N Diagnostics
